|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| C07K2299/00 | (2013.01) | ||
| A61K 39/00 | (2006.01) | ||
| A61P 15/00 | (2018.01) | ||
| A61P 11/00 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 13/02 | (2006.01) | ||
| A61P 11/00 | (2018.01) | ||
| A61P 13/10 | (2006.01) | ||
| A61P 13/02 | (2018.01) | ||
| A61P 17/00 | (2018.01) | ||
| A61P 15/00 | (2006.01) | ||
| A61P 17/00 | (2006.01) | ||
| C07K 16/2818 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| C07K 16/2878 | (2013.01) | ||
| A61P 13/10 | (2018.01) | ||
| A61P 13/12 | (2006.01) | ||
| C07K2317/92 | (2013.01) | ||
| A61P 13/12 | (2018.01) | ||
| C07K2317/55 | (2013.01) | ||
| C07K2317/75 | (2013.01) | ||
| A61K2039/505 | (2013.01) | ||
| C07K2317/34 | (2013.01) | ||
| C07K2317/24 | (2013.01) | ||
| C07K2317/90 | (2013.01) | ||
| C07K2317/35 | (2013.01) | ||
| C07K2317/71 | (2013.01) |
| (11) | Number of the document | 3494139 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17754895.5 |
| Date of filing the European patent application | 2017-08-04 | |
| (97) | Date of publication of the European application | 2019-06-12 |
| (45) | Date of publication and mention of the grant of the patent | 2022-01-12 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2017/045642 |
| Date | 2017-08-04 |
| (87) | Number | WO 2018/027204 |
| Date | 2018-02-08 |
| (30) | Number | Date | Country code |
| 201662371671 P | 2016-08-05 | US |
| (72) |
HARRIS, Seth , US
LAZAR, Greg , US
YANG, Yanli , US
CHRISTENSEN, Erin H. , US
HANG, Julie , US
KIM, Jeong , US
|
| (73) |
F. Hoffmann-La Roche AG ,
Grenzacherstrasse 124, 4070 Basel,
CH
|
| (54) | MULTIVALENT AND MULTIEPITOPIC ANITIBODIES HAVING AGONISTIC ACTIVITY AND METHODS OF USE |
| MULTIVALENT AND MULTIEPITOPIC ANITIBODIES HAVING AGONISTIC ACTIVITY AND METHODS OF USE |